Immuno-oncology
Conference Coverage
APHINITY trial: Biomarker analysis IDs predictive, prognostic factors
CHICAGO – Higher levels of several immune markers confer better prognosis in HER2-positive breast cancer patients treated with trastuzumab and...
Article
Chemo-free neoadjuvant approaches emerge in NSCLC and breast cancer
Dr. Alan P. Lyss breaks down new data presented on immune checkpoint inhibitors in NSCLC and trastuzumab emtansine for HER2-positive breast cancer...
News
FDA approves pembrolizumab for advanced SCLC
The approval was based on an overall response rate of 19% in two nonrandomized trials.
From the Journals
Niraparib-pembrolizumab combo finds niche in breast, ovarian cancers
The combination had good antitumor activity, as well as good safety and tolerability, in patients with advanced TNBC or ovarian carcinoma who were...
Conference Coverage
Skin plus GI adverse events with checkpoint inhibitors linked to risk of additional adverse events
MILAN – Toxicities occurred early in treatment, and having both increased risk of adverse events in other organ systems.
Conference Coverage
EULAR issues guidelines on managing rheumatic complications of cancer immunotherapies
The new guidelines are tailored for rheumatologists, and address diagnosis and treatment.
Conference Coverage
Adding ipilimumab to nivolumab provides no benefit in SCC trial
CHICAGO – There was no difference in overall or progression-free survival between patients receiving ipilimumab plus nivolumab and those receiving...
Conference Coverage
Adjuvant immunotherapy results ‘encouraging’ in early NSCLC
CHICAGO – About one-fifth of patients with resectable non–small cell lung cancer had major pathological responses with atezolizumab monotherapy...
Conference Coverage
Nivo/ipi shrinks early NSCLC before surgery
CHICAGO – Among patients who went on to resection, 44% of those who had received neoadjuvant nivolumab and ipilimumab had a major pathological...
From the Journals
Checkpoint inhibitor rechallenge is possible for select patients
Rechallenge resulted in the recurrence of a grade 2 or higher immune-related adverse event (irAE) in 55% of rechallenged patients, but no deaths...
Conference Coverage
Pembrolizumab improves 5-year OS in advanced NSCLC
CHICAGO – In a phase 1b trial of pembrolizumab, the 5-year OS rate was 23.2% in treatment-naive patients and 15.5% in previously treated patients...